Clene Readying for HEALEY Trial Results of CNM-Au8 in Slowing ALS

Clene Readying for HEALEY Trial Results of CNM-Au8 in Slowing ALS

296835

Clene Readying for HEALEY Trial Results of CNM-Au8 in Slowing ALS

Clene and its subsidiary Clene Nanomedicine are negotiating to increase their manufacturing capacity as they prepare to release findings — expected early next year — from a pivotal and enrolling Phase 3 trial of CNM-Au8 as an oral therapy aiming to slow amyotrophic lateral sclerosis (ALS) progression. Negotiations include the leasing of a 75,000 square foot facility in Elkton, Maryland, close to Clene’s current manufacturing site. The companies also entered into a loan agreement worth up to $30 million,…

You must be logged in to read/download the full post.